TY - JOUR T1 - Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates TT - JF - انستیتو-پاستور-ایران JO - انستیتو-پاستور-ایران VL - 21 IS - 4 UR - http://ibj.pasteur.ac.ir/article-1-1995-en.html Y1 - 2017 SP - 270 EP - 274 KW - Conjugation KW - Dithiothreitol KW - Antibody drug conjugate N2 - Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, temperature conditions, and DTT exposure times on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE analysis were used to evaluate free thiols produced and confirm the reduction process, respectively. Results: DTT concentration seems to be a potential factor in the reduction process. Concentrations of 0.1, 1, 5, 10, 20, 50, and 100 mM DTT at 37°C for 30 minutes resulted in approximately 0.4, 1.2, 5.4, 7, 8, 8, and 8 thiols per antibody, respectively. Conclusion: Optimized site-specific conjugation can provide better process control and reproducibility for the development of disulfide-based ADCs. M3 10.18869/acadpub.ibj.21.4.270 ER -